Avid Bioservices Inc (CDMO)

[biopharm]

Is it all about milestones or royalties or FDA approvals or other CDMO contracts?

I always liked to push the envelope and always questioned anything to everything, but I guess we can all agree that not big advancements would be possible without imaging technologies. As said before Big Pharma used to be allowed legally to pay off up and coming technologies from smaller biotechs that threatened Billion dollar patented toxic drugs that were approved based upon decreasing the size of the tumor lol

Imagine that....just because toxic drugs were killing you the damn FDA approved them for years

Imaging changed that course and we KNOW Roche has been playing with PS Targeting imaging for years YEARS

_______

Imaging allows proof of Biomarkers and proof of toxicities and proof that the FDA has been approving many drugs for years on a major flaw, but that is because Big Pharma lobbyists are #1 and being #1 is not always great because as said before a picture is worth a thousand words and a thousand words tucked into a bill for legislatures to approve are worthless

Imaging from GE, ThermoFisher etc etc based upon PS Targeting ...then utilized by Google or Amazon or IBM Watson or Microsoft etc will be the key

Why did John Springs Stafford show up when he had employees that are ok with being fined for trading etc and how many other traders are connected by the hip with Ronin?

https://www.sec.gov/Archives/edgar/data/704562/000101968710001070/filename1.htm


Things should become more interesting when all involved become public, then combined with years of sabotage to limit and conceal the value behind PS Targeting ...many will look like fools for accepting new jobs or other incentives all just to delay PS Targeting

________



Roche: The ultimate insider view

Medical imaging plays an increasingly important role in the development of new drugs

And how does imaging fit into research and development at Roche? Three years ago, Roche formed an Imaging Sciences group within the TRS organization (led by Anna-Lena Nordström) in recognition that more and more pRED projects are using imaging technology to improve the understanding of disease biology and to aid in drug development.

Since that time, part of the original imaging group has been integrated into Oncology Discovery & Translational Area (DTA) and is now named Oncology Translational Imaging (OTI). Team members include Abi Keelara, Tapan Nayak, Jean Tessier and Gudrun Zahlmann. The group’s expertise helps pRED colleagues answer important questions like: Does the drug reach the tumor? Is the drug causing pharmacodynamics changes in a patient’s tumor? Is the drug causing the tumor to change shape or size? In some cases, imaging can help with decisions regarding which dose should be used.

“In the Oncology DTA, non-invasive imaging tools are used alongside with tissue-based diagnostics to gain a more complete view of disease and response to therapies. This helps to improve decision making,” explains David Geho, who heads the OTI group.

Among the imaging modalities used in pRED projects are MRI, Positron Emission Tomography (PET), and CT scans. These can be used in global, multicenter studies and have contributed to decision making across multiple oncology programs. The OTI team is also exploring the use of advanced image analysis tools to assess changes in three-dimensional (3-D) tumor volumes as a means to more sensitively detect treatment effects on tumors.

In addition to the in-house experts on the Imaging Sciences team, Roche benefits from academic alliances such as the Dutch Imaging Hub (DIH). The hub connects pRED with three world-renowned institutes for advanced imaging: Free University Medical Center in Amsterdam, University Medical Center Groningen, and Radboud University Nijmegen Medical Center. Eight Roche postdocs and PhDs are working on numerous studies in oncology as part of the DIH collaboration.

Both OTI and the experts at the DIH are keenly interested if radiolabeled therapeutic antibodies (often called “radiotracers”) can be used in drug development. PET scanning with these tracers has been incorporated into several oncology programs to assess the drug’s tumor-targeting characteristics and to show how a new drug is distributed within the patient’s body.

“We are eager to work with pRED development teams on the implementation of molecular imaging tools that will enable us to make better drug development decisions,” David says.

http://www.roche.com/media/roche_stories/roche-stories-2013-10-03.htm

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=93323563

_______________